BRPI0906797A2 - Inibidores de anidrase carbônica ix - Google Patents

Inibidores de anidrase carbônica ix

Info

Publication number
BRPI0906797A2
BRPI0906797A2 BRPI0906797-3A BRPI0906797A BRPI0906797A2 BR PI0906797 A2 BRPI0906797 A2 BR PI0906797A2 BR PI0906797 A BRPI0906797 A BR PI0906797A BR PI0906797 A2 BRPI0906797 A2 BR PI0906797A2
Authority
BR
Brazil
Prior art keywords
carbonic anhydrase
anhydrase inhibitors
inhibitors
carbonic
anhydrase
Prior art date
Application number
BRPI0906797-3A
Other languages
English (en)
Inventor
Craig Zimmerman
John W Babich
John Joyal
Genliang Lu
Kevin P Maresca
Chris Barone
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Publication of BRPI0906797A2 publication Critical patent/BRPI0906797A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0906797-3A 2008-01-09 2009-01-08 Inibidores de anidrase carbônica ix BRPI0906797A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2004308P 2008-01-09 2008-01-09
US8898008P 2008-08-14 2008-08-14
US14200208P 2008-12-31 2008-12-31
PCT/US2009/030487 WO2009089383A2 (en) 2008-01-09 2009-01-08 Inhibitors of carbonic anhydrase ix

Publications (1)

Publication Number Publication Date
BRPI0906797A2 true BRPI0906797A2 (pt) 2015-07-14

Family

ID=40344470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906797-3A BRPI0906797A2 (pt) 2008-01-09 2009-01-08 Inibidores de anidrase carbônica ix

Country Status (9)

Country Link
US (1) US8877970B2 (pt)
EP (2) EP2240171B1 (pt)
JP (1) JP2011509304A (pt)
CN (1) CN102083427B (pt)
AU (2) AU2009204133B2 (pt)
BR (1) BRPI0906797A2 (pt)
CA (1) CA2711678A1 (pt)
RU (1) RU2498798C2 (pt)
WO (1) WO2009089383A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
BRPI0906797A2 (pt) 2008-01-09 2015-07-14 Molecular Insight Pharm Inc Inibidores de anidrase carbônica ix
WO2010065906A2 (en) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
EP2373622A2 (en) * 2008-12-05 2011-10-12 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
WO2011098610A1 (en) 2010-02-12 2011-08-18 Universita Degli Studi Di Firenze Carbonic anhydrase inhibitors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN103221388B (zh) * 2010-07-09 2016-09-28 维理生物技术公司 用于抑制转移性肿瘤生长的新型磺酰胺化合物
NL1038473C2 (en) 2010-12-24 2012-06-27 Centre Nat Rech Scient Cancer targeting using carbonic anhydrase isoform ix inhibitors.
WO2012175654A1 (en) 2011-06-23 2012-12-27 Facultes Universitaires Notre-Dame De La Paix Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders
US9371360B2 (en) 2011-11-30 2016-06-21 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof
AU2013207486A1 (en) 2012-01-06 2014-08-21 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
SG10201706618UA (en) 2012-11-15 2017-09-28 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
HUE044552T2 (hu) 2013-01-14 2019-11-28 Molecular Insight Pharm Inc Triazinalapú radiogyógyszerek és radiológiai képalkotó ágensek
AU2014220705C1 (en) * 2013-02-22 2018-10-18 Wilex Ag CAIX stratification based cancer treatment
WO2015025283A2 (en) 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
EP3495355A1 (en) 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10857246B2 (en) * 2015-06-01 2020-12-08 The Johns Hopkins University Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
WO2017054907A1 (en) 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
CN106867514B (zh) * 2015-12-11 2019-01-22 中国科学院大连化学物理研究所 一种用于比率识别人碳酸酐酶的小分子荧光探针及其合成方法和应用
EP3429637A4 (en) 2016-03-16 2020-03-11 Endocyte, Inc. CONJUGATES OF CARBONIC ANHYDRASE IX INHIBITORS AND USES THEREOF
AU2017234676A1 (en) * 2016-03-16 2018-09-20 Purdue Research Foundation Carbonic anhydrase IX targeting agents and methods
JP7030061B2 (ja) * 2016-05-13 2022-03-04 ザ・ジョンズ・ホプキンス・ユニバーシティ 炭酸脱水酵素ｉｘを標的にする核造影および放射性治療剤ならびにそれらの使用
CN109722230B (zh) * 2017-10-27 2021-07-23 中石化石油工程技术服务有限公司 一种油基钻井液用乳化剂及其制备方法和钻井液
CN112638919A (zh) * 2018-08-30 2021-04-09 日本医事物理股份有限公司 放射性咪唑并噻二唑衍生物化合物
US20220056001A1 (en) * 2018-12-19 2022-02-24 Purdue Research Foundation Carbonic anhydrase inhibitors and antibiotics against multidrug resistant bacteria
CN110790724B (zh) * 2019-09-20 2023-01-31 中山大学 一种选择性碳酸酐酶抑制剂及其合成方法和应用
CN114890928B (zh) * 2022-03-22 2024-02-23 厦门倍博特医学科技有限公司 一种异硫氰酸酯衍生物及其制备方法和用途
CN114835706B (zh) * 2022-05-11 2023-10-27 昆明理工大学 一种n^n配体及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
JP3051497B2 (ja) * 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
NZ244613A (en) 1991-10-29 1996-05-28 Bracco International B V Subst A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
CA2161376C (en) * 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium
JP2856098B2 (ja) * 1995-04-11 1999-02-10 日本製紙株式会社 感熱記録シート
JP3029010B2 (ja) * 1995-04-26 2000-04-04 日本製紙株式会社 感熱記録シート
US5957843A (en) * 1995-08-14 1999-09-28 Board Of Trustees Of The Leland Stanford Junior University Partial flyback echo-planar imaging
AU743489B2 (en) 1998-03-19 2002-01-24 Pharmacia & Upjohn Company 1,3,4-thiadiazoles useful for the treatment of CMV infections
ATE309205T1 (de) * 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
JPWO2002094261A1 (ja) 2001-05-24 2004-09-02 呉羽化学工業株式会社 含窒素化合物からなるｃｘｃｒ４拮抗作用を有する薬剤
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
JP4303595B2 (ja) 2001-12-21 2009-07-29 透 小池 アニオン性置換基を有する物質を捕捉可能な亜鉛錯体
US7381399B2 (en) 2002-03-11 2008-06-03 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
HUE028349T2 (en) * 2002-11-26 2016-12-28 Inst Virology CAIX-specific inhibitors
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
US6699958B1 (en) * 2003-02-13 2004-03-02 Borden Chemical, Inc. Colorless phenol-formaldehyde resins that cure colorless
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
JP2007513928A (ja) 2003-12-12 2007-05-31 オサケユイチア ユバンティア ファーマ リミティド ソマトスタチン受容体サブタイプ１（ｓｓｔｒ１）活性化合物及び治療におけるその使用
AU2005215510A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
JP4790012B2 (ja) * 2005-04-27 2011-10-12 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 高親和性の分子イメージングプローブをスクリーニングするためのインサイチュクリックケミストリー法
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
EP1940841B9 (fr) * 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007090461A1 (en) 2006-02-06 2007-08-16 Ciba Holding Inc. Use of metal complex compounds as oxidation catalysts
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
BRPI0712930A2 (pt) 2006-06-20 2012-10-02 Ishihara Sangyo Kaisha pesticida contendo derivado de piridil-metanamina ou seu sal
WO2008028000A2 (en) 2006-08-29 2008-03-06 Molecular Insight Pharmaceuticals, Inc. Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases
PL2942065T3 (pl) 2006-11-08 2018-11-30 Molecular Insight Pharmaceuticals, Inc. Heterodimery kwasu glutamowego
WO2008124703A2 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
BRPI0906797A2 (pt) 2008-01-09 2015-07-14 Molecular Insight Pharm Inc Inibidores de anidrase carbônica ix
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
EP2373622A2 (en) 2008-12-05 2011-10-12 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer

Also Published As

Publication number Publication date
EP2823826A3 (en) 2015-03-25
JP2011509304A (ja) 2011-03-24
CN102083427A (zh) 2011-06-01
RU2498798C2 (ru) 2013-11-20
AU2009204133A1 (en) 2009-07-16
US8877970B2 (en) 2014-11-04
EP2823826A2 (en) 2015-01-14
CA2711678A1 (en) 2009-07-16
RU2010132910A (ru) 2012-02-20
WO2009089383A3 (en) 2009-09-03
US20090175794A1 (en) 2009-07-09
CN102083427B (zh) 2014-12-10
WO2009089383A2 (en) 2009-07-16
EP2240171B1 (en) 2014-08-13
EP2240171A2 (en) 2010-10-20
AU2014202811A1 (en) 2014-06-12
AU2009204133B2 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
BRPI0906797A2 (pt) Inibidores de anidrase carbônica ix
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
NL300962I1 (nl) patiromer sorbitex calcium
NL300891I2 (nl) Lotilaner en zouten daarvan
BRPI0917808A2 (pt) inibidores de cmet
BRPI0907457A2 (pt) Absorventes
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0912271A2 (pt) co-autoria estruturada
BRPI0918564A2 (pt) inibidores
DK2323515T3 (da) Beholderholder med fastgørelsesmidler
BRPI0911625A2 (pt) Métodos
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK2240506T3 (da) IAP inhibitorer
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
GB201017098D0 (en) Carbonic anhydrase inhibitors
GB201002412D0 (en) Carbonic anhydrase inhibitors
UA16451S (uk) Тумба
UA16452S (uk) Тумба
UA17846S (uk) Тумба
UA17998S (uk) Тумба

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.